Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Symposium 2024 report: ‘Sepsis – a brighter hope for tomorrow’

Thursday, October 31, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Volition's report from the 'NETs in sepsis management' symposium at ESICM Lives 2024 highlighted significant research outcomes from three independent studies involving over 3,000 sepsis patients. These studies utilized Nu.Q® NETs to assess circulating H3.1 nucleosome levels, which serve as a surrogate marker for Neutrophil Extracellular Traps (NETs). The findings suggest a brighter future for sepsis management.
Price reaction · baseline $12.14 (2024-10-30 close) · hit pre-market · 1 other VNRX headline(s) in the window, move may be shared
day 0 close · peak
-9.4%
day 1
-0.4%
day 3
-1.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • The symposium presented promising research findings.
  • Involvement of over 3,000 sepsis patients indicates robust data.
  • Nu.Q® NETs show potential in sepsis management.

Full Press Release Details

Volition published a report from its ‘NETs in sepsis management’ symposium at ESICM Lives 2024.
The symposium explored research findings from three large, independent studies involving more than 3,000 sepsis patients. The studies used Nu.Q® NET s to measure levels of circulating H3.1 nucleosomes in the bloodstream, a surrogate marker for Neutrophil Extracellular Traps (NETs).

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What was the focus of the symposium at ESICM Lives 2024?

The symposium focused on 'NETs in sepsis management' and presented research findings.

How many patients were involved in the studies discussed?

The studies involved more than 3,000 sepsis patients.

What marker was measured in the studies?

The studies measured circulating H3.1 nucleosomes as a surrogate marker.

What technology did the studies utilize?

The studies used Nu.Q® NETs to assess levels of nucleosomes in the bloodstream.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Volition sepsis Nu.Q® NETs ESICM Lives 2024 H3.1 nucleosomes
Last updated: Oct 31, 2024

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk